Edn1 Antibody

What is Endothelin-1 and why is it important in research?

Endothelin-1 is an endothelium-derived vasoconstrictor peptide that functions as a ligand for G-protein coupled receptors EDNRA and EDNRB. It activates PTK2B, BCAR1, BCAR3, and GTPases RAP1 and RHOA cascade in glomerular mesangial cells . EDN1 is important in research because it has been implicated in multiple pathological processes including cancer progression, viral pathogenesis, and vascular disorders. Its biological roles extend to promoting cell proliferation, migration, invasion, angiogenesis, and epithelial-mesenchymal transition (EMT) .

What types of EDN1 antibodies are available for research applications?

Both monoclonal and polyclonal antibodies targeting EDN1 are available for research. Monoclonal antibodies offer high specificity for particular epitopes, while polyclonal antibodies recognize multiple epitopes, potentially providing higher sensitivity. Available options include:

How does the EDN1 signaling pathway work?

The EDN1 signaling pathway begins with the translation of preproET-1, encoded by the EDN1 gene on chromosome 6. Through proteolytic cleavage by a signal peptidase and proprotein convertase (often furin-type), inactive big-ET-1 is produced. Endothelin-converting enzyme (ECE) then cleaves big-ET-1 to generate the active ligand ET-1 .

Activation of EDN1 gene occurs in response to stimuli including hypoxia, angiotensin II, cytokines, shear stress, insulin, growth factors, and ischemia. Once released from smooth muscle cells and endothelial cells, ET-1 signals in an autocrine or paracrine manner . It binds primarily to EDNRA and EDNRB receptors, triggering downstream signaling cascades including ROCK signaling, which can lead to nuclear translocation of NFATC3 and subsequent transcriptional activation .

What are the optimal dilutions for using EDN1 antibodies in different applications?

Optimal dilutions vary depending on the specific antibody and application. Based on the available literature, the following ranges are recommended:

Researchers should perform titration experiments to determine the optimal concentration for their specific experimental system .

How should EDN1 antibodies be stored to maintain efficacy?

To maintain antibody efficacy:

• Store at 4°C for frequent use (short-term storage)

• Store at -20°C in a manual defrost freezer for long-term storage (up to two years without detectable loss of activity)

• Avoid repeated freeze-thaw cycles which can compromise antibody functionality

• Aliquot the antibody solution to minimize freeze-thaw cycles

• Most EDN1 antibodies are supplied in buffer containing preservatives (such as 0.02% sodium azide) and stabilizers (such as 50% glycerol) to maintain stability

Thermal stability tests demonstrate less than 5% loss rate when antibodies are incubated at 37°C for 48 hours, indicating good stability under appropriate storage conditions .

What controls should be included when using EDN1 antibodies in experimental procedures?

For rigorous experimental design with EDN1 antibodies, include:

• Positive controls:

  • Known EDN1-expressing tissues/cells (vascular endothelial cells are recommended)

  • Recombinant EDN1 protein for Western blotting

  • Validated positive control samples provided by antibody manufacturers

• Negative controls:

  • Primary antibody omission control

  • Isotype control (matching IgG from the same species)

  • EDN1 knockdown samples (siRNA treated cells)

  • Tissues from EDN1 knockout models when available

• Validation controls:

  • Peptide competition assay to confirm specificity

  • Multiple antibodies recognizing different epitopes of EDN1

  • Correlation of results across different detection methods (e.g., mRNA expression with protein levels)

How can I differentiate between preproET-1, big-ET-1, and mature ET-1 using antibodies?

Differentiating between EDN1 precursors and mature peptide requires careful antibody selection:

• Epitope mapping: Select antibodies that recognize specific regions unique to each form:

  • Antibodies against the C-terminal region can detect mature ET-1 (21 amino acids)

  • Antibodies against the Big-ET-1 specific junctional region detect only the precursor

  • Antibodies against preproET-1 N-terminal sequences detect only the prepro form

• Western blotting differentiation:

  • PreproET-1: ~24.4 kDa band

  • Big-ET-1: ~4.3 kDa band

  • Mature ET-1: ~2.5 kDa band

• Sequential immunoprecipitation approach:

  • Use antibodies specific to mature ET-1 to deplete samples

  • Then probe with antibodies recognizing precursor forms

• Combined analysis:

  • Use ECE inhibitors to block conversion of Big-ET-1 to ET-1

  • Compare antibody reactivity before and after inhibition

How can EDN1 antibodies be used to investigate EDN1/EDNR signaling in cancer progression?

EDN1 antibodies have been instrumental in elucidating the role of EDN1/EDNR signaling in cancer:

• Expression analysis:

  • Quantify EDN1 protein levels in tumor vs. normal tissues using IHC or Western blotting

  • Correlate with EDNRA/EDNRB receptor expression patterns

  • Assess expression in relation to tumor stage and prognosis

• Mechanistic studies:

  • Detect EDN1 secretion in cell culture supernatants following genetic manipulation

  • Monitor changes in downstream signaling (e.g., ROCK pathway activation) using phospho-specific antibodies

  • Visualize subcellular localization changes in response to receptor activation

• Functional investigations:

  • Combine with cell proliferation assays (e.g., CCK-8) to assess growth effects

  • Use in migration/invasion assays to evaluate metastatic potential

  • Employ in angiogenesis assays to measure VEGF production

• Therapeutic targeting studies:

  • Evaluate effects of EDNR antagonists on EDN1 signaling

  • Assess efficacy of combination therapies targeting the EDN1 axis

  • Monitor treatment resistance mechanisms

Results from colorectal cancer studies demonstrate that EDN1 overexpression significantly increases cell proliferation and migration, while EDN1 knockdown inhibits these processes, suggesting EDN1 as a potential therapeutic target .

What approaches can resolve contradictory results when using different EDN1 antibodies?

When different EDN1 antibodies yield contradictory results:

• Epitope mapping analysis:

  • Determine exactly which regions of EDN1 each antibody recognizes

  • Consider whether post-translational modifications might affect epitope accessibility

  • Evaluate potential cross-reactivity with EDN2 or EDN3 due to sequence homology

• Validation through orthogonal methods:

  • Confirm protein expression using mass spectrometry

  • Correlate with mRNA expression data (RT-qPCR)

  • Validate through genetic manipulation (overexpression/knockdown)

• Comprehensive controls:

  • Use tissues from EDN1 knockout models as negative controls

  • Include recombinant EDN1 protein as positive control

  • Perform peptide competition assays to confirm specificity

• Multi-antibody approach:

  • Apply multiple antibodies targeting different epitopes

  • Compare monoclonal vs. polyclonal antibodies

  • Use antibodies from different manufacturers

• Standardization of protocols:

  • Optimize fixation conditions for IHC/ICC

  • Standardize lysis conditions for Western blotting

  • Consider native vs. denaturing conditions for protein detection

How can EDN1 antibodies be used to study virus-induced pathogenesis?

EDN1 antibodies have been valuable in investigating virus-induced pathogenesis:

• Expression analysis in viral models:

  • Measure EDN1 levels in virus-infected vs. uninfected tissues

  • Track temporal changes in EDN1 expression following infection

  • Correlate with markers of disease progression

• Cellular infiltration studies:

  • Use EDN1 antibodies in conjunction with immune cell markers

  • Assess correlation between EDN1 levels and infiltration of specific cell types

  • Quantify changes in co-stimulatory molecules on infiltrating cells

• Mechanistic investigations:

  • Evaluate EDN1's role in chemokine/cytokine upregulation during infection

  • Assess the impact on viral replication using viral RNA quantification

  • Study T-cell responses through IFN-γ and IL-17A expression analysis

Research using Theiler's murine encephalomyelitis virus (TMEV) demonstrates that ET-1 elevation significantly affects upregulation of chemokines (CCL2, CXCL1), cytokines, and viral RNA. ET-1 treated mice showed approximately 2-fold higher proportions and numbers of infiltrating cells in the CNS .

What protocol modifications are needed when using EDN1 antibodies in skin research models?

When studying EDN1 in skin research models:

• Tissue preparation considerations:

  • Optimize fixation protocols (brief fixation times may preserve epitopes better)

  • Consider cryosections for certain epitopes that may be sensitive to paraffin embedding

  • Use antigen retrieval methods appropriate for skin tissue

• UVR exposure models:

  • When studying UVR responses, carefully time sample collection (24, 48, 72, and 96 hours post-exposure)

  • Use co-immunostaining approaches (e.g., EDN1 with proliferation markers like PCNA or Ki67)

  • Include DNA damage markers (e.g., CPD) to correlate with EDN1 expression

• Cell-specific analysis:

  • Use co-staining with cell-type markers (e.g., TRP1 for melanocytes)

  • Employ laser capture microdissection to isolate specific cell populations

  • Consider in situ approaches to visualize EDN1 mRNA and protein simultaneously

• Signaling pathway investigation:

  • Use receptor antagonists (e.g., BQ788 for EDNRB) to block specific pathways

  • Correlate EDN1 expression with downstream effectors

  • Compare keratinocyte and melanocyte responses

Research has demonstrated that keratinocytic EDN1 in a non-cell autonomous manner controls melanocyte proliferation, migration, DNA damage response, and apoptosis following UVB exposure, highlighting the importance of EDN1/EDNRB signaling in UV-induced melanocyte activation .

How can EDN1 antibodies help investigate the relationship between EDN1 and VEGF in angiogenesis?

EDN1 antibodies can elucidate the EDN1-VEGF relationship in angiogenesis through:

• Co-expression analysis:

  • Perform dual immunostaining for EDN1 and VEGF

  • Quantify correlation between EDN1 and VEGF expression patterns

  • Analyze in both normal and pathological tissues (particularly tumors)

• Sequential signaling studies:

  • Use EDN1 antibodies to detect changes in EDN1 protein levels following hypoxia

  • Correlate with subsequent VEGF production

  • Monitor the temporal relationship between EDN1 activation and VEGF release

• Receptor-specific investigations:

  • Combine with ETAR antagonists (e.g., BQ-123) to determine receptor specificity

  • Assess VEGF expression after receptor blockade

  • Evaluate changes in downstream signaling pathways

• Genetic manipulation approaches:

  • Use EDN1 antibodies to confirm knockdown/overexpression efficiency

  • Measure corresponding changes in VEGF expression

  • Assess functional outcomes through angiogenesis assays

Studies in ovarian carcinoma cells have shown that ET-1 stimulation increases VEGF production approximately twofold compared to controls. This stimulation appears to signal through ETAR, as the ETAR antagonist BQ-123 inhibits VEGF production. Similar findings in lung cancer indicate that silencing ET-1 using RNAi decreases VEGF expression and impairs A549 cell proliferation .

How can I address high background issues when using EDN1 antibodies for immunohistochemistry?

To reduce high background in EDN1 immunohistochemistry:

• Blocking optimization:

  • Extend blocking time (1-2 hours)

  • Try different blocking reagents (BSA, serum, commercial blockers)

  • Consider dual blocking (protein block followed by serum block)

• Antibody dilution adjustment:

  • Further dilute primary antibody (start with manufacturer recommendations, then optimize)

  • Optimize incubation conditions (4°C overnight may reduce background)

  • For IHC-P applications, dilutions of 1:50-1:100 are typically recommended

• Washing modifications:

  • Increase wash duration and number of washes

  • Add 0.1-0.3% Triton X-100 to wash buffers

  • Consider using TBS instead of PBS for certain applications

• Tissue preparation improvements:

  • Optimize fixation protocol (overfixation can increase background)

  • Ensure complete deparaffinization

  • Try different antigen retrieval methods (citrate vs. EDTA buffers)

• Detection system considerations:

  • Switch detection systems (HRP vs. AP)

  • Use polymer-based detection instead of avidin-biotin

  • Consider fluorescent detection which may provide better signal-to-noise ratio

What are the most effective strategies for validating EDN1 antibody specificity?

For comprehensive EDN1 antibody validation:

• Genetic approaches:

  • Test antibody in EDN1 knockout/knockdown systems

  • Compare with EDN1 overexpression models

  • Use CRISPR-edited cell lines with specific EDN1 mutations

• Peptide competition:

  • Pre-incubate antibody with excess immunogen peptide

  • Compare staining pattern with and without competition

  • True signal should be eliminated by competition

• Multi-technique validation:

  • Confirm Western blot results match immunostaining patterns

  • Correlate protein detection with mRNA expression data

  • Use multiple antibodies targeting different epitopes

• Species reactivity confirmation:

  • Test across relevant species (human, mouse models)

  • Verify homology at epitope regions

  • Many EDN1 antibodies show reactivity across human and mouse samples

• Cross-reactivity assessment:

  • Test against EDN2 and EDN3 to ensure specificity

  • Evaluate potential cross-reactivity with big-ET-1 vs. mature ET-1

  • Consider endothelin-converting enzyme inhibitors to distinguish precursor forms